Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 207

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Hippo signalling in the liver: role in development, regeneration and disease

Open access
Russell, Jacquelyn O., Camargo, Fernando D. · 2022 · Nature Reviews Gastroenterology & Hepatology

Abstract

The Hippo signalling pathway has emerged as a major player in many aspects of liver biology, such as development, cell fate determination, homeostatic function and regeneration from injury. The regulation of Hippo signalling is complex, with activation of the pathway by diverse upstream inputs including signals from cellular adhesion, mechanotransduction and crosstalk with other signalling pathways. Pathological activation of the downstream transcriptional co-activators yes-associated protein 1 (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ, encoded by WWTR1), which are negatively regulated by Hippo signalling, has been implicated in multiple aspects of chronic liver disease, such as the development of liver fibrosis and tumorigenesis. Thus, development of pharmacological inhibitors of YAP–TAZ signalling has been an area of great interest. In this Review, we summarize the diverse roles of Hippo signalling in liver biology and highlight areas where outstanding questions remain to be investigated. Greater understanding of the mechanisms of Hippo signalling in liver function should help facilitate the development of novel therapies for the treatment of liver disease. In this Review, Russell and Camargo summarize the role of the Hippo signalling pathway in liver development, homeostasis, regeneration and disease, and discuss development of potential therapeutics for liver diseases such as fibrosis and cancer. During embryonic liver development, yes-associated protein 1 (YAP) activity in hepatoblasts suppresses hepatocyte differentiation and is essential for proper cholangiocyte maturation and formation of the intrahepatic biliary network. During adult liver homeostasis, YAP activity is largely dispensable in hepatocytes but is required for the maintenance of mature cholangiocytes through its protective effects against exposure to hydrophobic bile acids. YAP is an important regulator of liver cell fate owing to its ability to promote hepatocyte-to-cholangiocyte transdifferentiation, and its activity in cholangiocytes drives the ductular reaction during chronic liver injury. YAP–transcriptional co-activator with PDZ-binding motif (TAZ) activity in hepatocytes, hepatic stellate cells, Kupffer cells and liver sinusoidal endothelial cells promotes inflammation and fibrosis in multiple models of nonalcoholic steatohepatitis and chemical-induced liver fibrosis. YAP is a potent oncogene and high YAP activity is frequently observed in hepatocellular carcinoma, hepatoblastoma and cholangiocarcinoma, where it promotes tumour cell proliferation, drug resistance and potentially immune evasion. Pharmacological targeting of YAP–TAZ holds great potential, either through inhibition of YAP–TAZ activity for anti-cancer or anti-fibrotic therapies or through promotion of YAP–TAZ activity to enhance liver regeneration. During embryonic liver development, yes-associated protein 1 (YAP) activity in hepatoblasts suppresses hepatocyte differentiation and is essential for proper cholangiocyte maturation and formation of the intrahepatic biliary network. During adult liver homeostasis, YAP activity is largely dispensable in hepatocytes but is required for the maintenance of mature cholangiocytes through its protective effects against exposure to hydrophobic bile acids. YAP is an important regulator of liver cell fate owing to its ability to promote hepatocyte-to-cholangiocyte transdifferentiation, and its activity in cholangiocytes drives the ductular reaction during chronic liver injury. YAP–transcriptional co-activator with PDZ-binding motif (TAZ) activity in hepatocytes, hepatic stellate cells, Kupffer cells and liver sinusoidal endothelial cells promotes inflammation and fibrosis in multiple models of nonalcoholic steatohepatitis and chemical-induced liver fibrosis. YAP is a potent oncogene and high YAP activity is frequently observed in hepatocellular carcinoma, hepatoblastoma and cholangiocarcinoma, where it promotes tumour cell proliferation, drug resistance and potentially immune evasion. Pharmacological targeting of YAP–TAZ holds great potential, either through inhibition of YAP–TAZ activity for anti-cancer or anti-fibrotic therapies or through promotion of YAP–TAZ activity to enhance liver regeneration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41575-021-00571-w

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Cited by

See all 207

Metadata

Authors
Russell, J. O., & Camargo, F. D.
Venue
Nature Reviews Gastroenterology & Hepatology
Published
2022-01-21
Volume
19
Issue
5
Pages
297-312
ISSN
  • 1759-5045 (ISSN-L)
  • 1759-5053
OpenAlex
W4206229901
Cited by
207
References
45
FWCI
6.07
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hippo signalling in the liver: role in development, regeneration and disease. https://app.cochat.ai/papers/10.1038/s41575-021-00571-w
The paper
Russell, J. O., & Camargo, F. D. (2022). Hippo signalling in the liver: role in development, regeneration and disease. Nature Reviews Gastroenterology & Hepatology. https://doi.org/10.1038/s41575-021-00571-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.